Previous Close | 1.0000 |
Open | 1.0500 |
Bid | 0.9000 |
Ask | 1.2000 |
Strike | 2.00 |
Expire Date | 2024-10-18 |
Day's Range | 1.0000 - 1.0500 |
Contract Range | N/A |
Volume | |
Open Interest | 870 |
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the appointment of Erik Ostrowski as Senior Vice President, Chief Financial Officer and Chief Business Officer. Mr. Ostrowski is an experienced biotech executive with a diverse background spanning industry leadership roles, board service and investment banking.
Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We don't wish...
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 4 newly-hired employees options to purchase an aggregate of 76,000 shares of Akebia's common stock on May 31, 2024, as inducements material to such employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).